文献速递泌尿生殖技术与安全US

靶向生物合成纳米气泡用于前列腺癌超声分子成像

Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Prostate Cancer.
PubMed 文献 · Ultrasound Med Biol · 2025-06-13

本研究将抗CD147纳米抗体通过马来酰亚胺-硫醇偶联化学定点偶联到生物合成气体囊泡上,制备CD147-hGVs超声分子成像探针。体外实验显示CD147-hGVs对PC-3细胞的结合亲和力较非靶向对照高约7倍(p<0.001),体内超声成像中肿瘤特异性信号增强持续>15分钟,对比度较Con-hGVs高约6倍(p<0.01)。

要点

  • CD147-hGVs在体内超声成像中产生肿瘤特异性信号增强,持续>15分钟。
  • CD147-hGVs对比度较Con-hGVs高约6倍(p<0.01),具备靶向对比能力。
  • 体外CD147-hGVs对PC-3细胞结合亲和力较非靶向对照高约7倍(p<0.001)。

核心结论

  • 抗CD147纳米抗体偶联的生物气体囊泡稳定性好、对前列腺癌细胞靶向能力增强,是用于超声成像及潜在治疗的前景良好的新型分子探针。

研究设计与样本

  • 临床前研究:用Mal-PEG2000-NHS异双功能交联剂经马来酰亚胺-硫醇偶联化学将抗CD147纳米抗体定点偶联到生物合成气体囊泡(hGVs);在PC-3细胞系行体外靶向验证(流式细胞术、细胞黏附、免疫荧光),在荷前列腺癌裸鼠中使用迈瑞Resona 9T临床超声诊断设备行体内超声成像。

关键影像表现/征象

  • CD147-hGVs在体内分子超声成像中产生肿瘤特异性信号增强,注射后持续>15分钟。
  • CD147-hGVs的对比度较Con-hGVs高约6倍(p<0.01)。

诊断标准与关键数值

  • CD147-hGVs第1天流体动力学直径234.4 ± 7.6 nm vs 第10天236.0 ± 9.8 nm(p = 0.32),持续单分散(PDI <0.2)。
  • 体外靶向实验中CD147-hGVs对PC-3细胞的结合亲和力较非靶向对照高约7倍(p < 0.001)。

临床应用与阅片要点

  • CD147-hGVs在荷前列腺癌裸鼠中可实现肿瘤特异性超声信号增强,信号持续>15分钟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: As the second leading cause of cancer-related mortality in males worldwide, prostate cancer (PCa) presents an urgent need for advanced molecular imaging strategies to improve diagnostic precision. This study presents CD147-targeted nanobody-conjugated biosynthetic gas vesicles (CD147-hGVs) as a high-performance ultrasound molecular imaging probe for precise and noninvasive diagnosis of PCa.

METHODS: Biosynthetic gas vesicles (hGVs) were site-specifically functionalized with anti-CD147 nanobodies via controlled maleimide-thiol conjugation chemistry using Mal-PEG2000-NHS heterobifunctional crosslinkers. Systematic characterization included stability assessments, in vitro targeting validation (flow cytometry, cell adhesion, and immunofluorescence on PC-3 cell lines), and in vivo ultrasound imaging in PCa-bearing nude mice using Clinical ultrasound diagnostic equipment Mindray Resona 9T.

RESULTS: CD147 -hGVs exhibited remarkable stability with sustained monodispersity (PDI <0.2) and consistent hydrodynamic diameter (234.4 ± 7.6 nm at day 1 vs 236.0 ± 9.8 nm at day 10, p = 0.32). In vitro targeting assays revealed about 7-fold higher binding affinity of CD147-hGVs to PC-3 cells compared to non-targeted controls (p < 0.001). In vivo molecular ultrasound imaging showed tumor-specific signal enhancement persisting for >15 min post-injection, with CD147-hGVs achieving about 6-fold higher contrast to Con-hGVs (p < 0.01).

CONCLUSION: Anti-CD147 nanobody conjugated biological gas vesicles exhibit excellent stability and enhanced targeting ability for prostate cancer cells, making them a promising novel molecular probe for ultrasound imaging and potential therapy for prostate cancer.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Liu T, Wang J, Cui T, et al. Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Prostate Cancer. Ultrasound Med Biol. 2025. PMID: 40517079. doi:10.1016/j.ultrasmedbio.2025.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。